These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 15477634

  • 1. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H, Chaudri-Ross HA.
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [Abstract] [Full Text] [Related]

  • 2. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
    Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA, Lang R.
    Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
    [Abstract] [Full Text] [Related]

  • 3. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE.
    J Clin Oncol; 2008 Apr 20; 26(12):1956-64. PubMed ID: 18332474
    [Abstract] [Full Text] [Related]

  • 7. Letrozole in advanced breast cancer: the PO25 trial.
    Mouridsen HT.
    Breast Cancer Res Treat; 2007 Apr 20; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340
    [Abstract] [Full Text] [Related]

  • 8. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    Breast International Group (BIG) 1-98 Collaborative GroupSenology Center of Eastern Switzerland, Kantonsspital, St. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.
    N Engl J Med; 2005 Dec 29; 353(26):2747-57. PubMed ID: 16382061
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF.
    Semin Oncol; 2006 Apr 29; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [Abstract] [Full Text] [Related]

  • 11. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R.
    Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902
    [Abstract] [Full Text] [Related]

  • 12. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun 15; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 13. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE.
    Clin Cancer Res; 1999 Sep 15; 5(9):2338-43. PubMed ID: 10499602
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Langecker P, Blanchett D.
    J Clin Oncol; 2007 Nov 01; 25(31):4961-6. PubMed ID: 17971594
    [Abstract] [Full Text] [Related]

  • 16. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Nov 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
    Ansari TN, Mahmood A, Hussain I, Samad A.
    J Coll Physicians Surg Pak; 2005 Apr 01; 15(4):204-6. PubMed ID: 15857590
    [Abstract] [Full Text] [Related]

  • 18. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [Abstract] [Full Text] [Related]

  • 19. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.